OBJECTIVE: To describe the design, recruitment and baseline characteristics of participants in a community pharmacy based pharmacogenetic study of antihypertensive drug treatment. SETTING: Participants enrolled from the population-based Pharmaco-Morbidity Record Linkage System. METHOD: We designed a nested case-control study in which we will assess whether specific genetic polymorphisms modify the effect of antihypertensive drugs on the risk of myocardial infarction. In this study, cases (myocardial infarction) and controls were recruited through community pharmacies that participate in PHARMO. The PHARMO database comprises drug dispensing histories of about 2,000,000 subjects from a representative sample of Dutch community pharmacies linked to the national registrations of hospital discharges. RESULTS: In total we selected 31010 patients (2777 cases and 28233 controls) from the PHARMO database, of whom 15973 (1871 cases, 14102 controls) were approached through their community pharmacy. Overall response rate was 36.3% (n = 5791, 794 cases, 4997 controls), whereas 32.1% (n = 5126, 701 cases, 4425 controls) gave informed consent to genotype their DNA. As expected, several cardiovascular risk factors such as smoking, body mass index, hypercholesterolemia, and diabetes mellitus were more common in cases than in controls. CONCLUSION: Furthermore, cases more often used beta-blockers and calcium-antagonists, whereas controls more often used thiazide diuretics, ACE-inhibitors, and angiotensin-II receptor blockers. We have demonstrated that it is feasible to select patients from a coded database for a pharmacogenetic study and to approach them through community pharmacies, achieving reasonable response rates and without violating privacy rules.
OBJECTIVE: To describe the design, recruitment and baseline characteristics of participants in a community pharmacy based pharmacogenetic study of antihypertensive drug treatment. SETTING:Participants enrolled from the population-based Pharmaco-Morbidity Record Linkage System. METHOD: We designed a nested case-control study in which we will assess whether specific genetic polymorphisms modify the effect of antihypertensive drugs on the risk of myocardial infarction. In this study, cases (myocardial infarction) and controls were recruited through community pharmacies that participate in PHARMO. The PHARMO database comprises drug dispensing histories of about 2,000,000 subjects from a representative sample of Dutch community pharmacies linked to the national registrations of hospital discharges. RESULTS: In total we selected 31010 patients (2777 cases and 28233 controls) from the PHARMO database, of whom 15973 (1871 cases, 14102 controls) were approached through their community pharmacy. Overall response rate was 36.3% (n = 5791, 794 cases, 4997 controls), whereas 32.1% (n = 5126, 701 cases, 4425 controls) gave informed consent to genotype their DNA. As expected, several cardiovascular risk factors such as smoking, body mass index, hypercholesterolemia, and diabetes mellitus were more common in cases than in controls. CONCLUSION: Furthermore, cases more often used beta-blockers and calcium-antagonists, whereas controls more often used thiazide diuretics, ACE-inhibitors, and angiotensin-II receptor blockers. We have demonstrated that it is feasible to select patients from a coded database for a pharmacogenetic study and to approach them through community pharmacies, achieving reasonable response rates and without violating privacy rules.
Authors: Ad M Knaapen; Hans B Ketelslegers; Ralph W H Gottschalk; Rob G J H Janssen; Aimee D C Paulussen; Hubert J M Smeets; Roger W L Godschalk; Frederik J Van Schooten; Jos C S Kleinjans; Joost H M Van Delft Journal: Clin Chem Date: 2004-09 Impact factor: 8.327
Authors: Olaf H Klungel; Edwin P Martens; Bruce M Psaty; Diederik E Grobbee; Sean D Sullivan; Bruno H Ch Stricker; Hubert G M Leufkens; A de Boer Journal: J Clin Epidemiol Date: 2004-12 Impact factor: 6.437
Authors: B R Davis; D K Arnett; E Boerwinkle; C E Ford; C Leiendecker-Foster; M B Miller; H Black; J H Eckfeldt Journal: Pharmacogenomics J Date: 2006-05-16 Impact factor: 3.550
Authors: D Cusi; C Barlassina; T Azzani; G Casari; L Citterio; M Devoto; N Glorioso; C Lanzani; P Manunta; M Righetti; R Rivera; P Stella; C Troffa; L Zagato; G Bianchi Journal: Lancet Date: 1997-05-10 Impact factor: 79.321
Authors: Isabelle Peytremann-Bridevaux; Julie Bordet; Valérie Santschi; Tinh-Hai Collet; Marc Eggli; Bernard Burnand Journal: Int J Public Health Date: 2012-07-01 Impact factor: 3.380
Authors: Bas J M Peters; Helmi Pett; Olaf H Klungel; Bruno H Ch Stricker; Bruce M Psaty; Nicole L Glazer; Kerri L Wiggins; Josh C Bis; Anthonius de Boer; Anke-Hilse Maitland-van der Zee Journal: Atherosclerosis Date: 2011-06-17 Impact factor: 5.162
Authors: F F Alharbi; P C Souverein; M C de Groot; A H Maitland-van der Zee; A de Boer; O H Klungel Journal: J Hum Hypertens Date: 2017-03-23 Impact factor: 3.012
Authors: Louise A Donnelly; Natalie R van Zuydam; Kaixin Zhou; Roger Tavendale; Fiona Carr; Anke H Maitland-van der Zee; Maarten Leusink; Anthonius de Boer; Pieter A Doevendans; Folkert W Asselbergs; Andrew D Morris; Ewan R Pearson; Olaf H Klungel; Alex S F Doney; Colin N A Palmer Journal: Pharmacogenet Genomics Date: 2013-10 Impact factor: 2.089
Authors: Seyed Hamidreza Mahmoudpour; Folkert W Asselbergs; Catherine E de Keyser; Patrick C Souverein; Albert Hofman; Bruno H Stricker; Anthonius de Boer; Anke-Hilse Maitland-van der Zee Journal: Int J Clin Pharm Date: 2015-07-10
Authors: D B M A van Wieren-de Wijer; A H Maitland-van der Zee; A de Boer; S V Belitser; A A Kroon; P W de Leeuw; P Schiffers; R G J H Janssen; C M van Duijn; B H C H Stricker; O H Klungel Journal: Eur J Epidemiol Date: 2009-09-17 Impact factor: 8.082
Authors: A G Veldhuis-Vlug; L Oei; P C Souverein; M W T Tanck; F Rivadeneira; M C Zillikens; P W Kamphuisen; A H Maitland-van der Zee; M C H de Groot; A Hofman; A G Uitterlinden; E Fliers; A de Boer; P H Bisschop Journal: Osteoporos Int Date: 2015-04-25 Impact factor: 4.507